Floatz logo

Regorafenib

Microsatellite Stable

CytoDyn, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Microsatellite Stable cohort.

Asset / SponsorPhaseRating
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Eloxatin
M.D. Anderson Cancer Center
Phase 2BB
Epirubicin
NextCure, Inc.
Phase 2B
Pembrolizumab
NextCure, Inc.
Phase 2B
Cyclophosphamide
NextCure, Inc.
Phase 2B

View all 18 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →